Skip to main content
. 2016 Nov 28;40(4):222–229. doi: 10.1002/clc.22649

Figure 2.

Figure 2

(A) Kaplan‐Meier estimates of ischemic stroke‐free survival in Chinese AF patients on warfarin and on a NOAC. (B) Kaplan‐Meier estimates of ischemic stroke‐free survival in Chinese AF patients on warfarin with TTR ≥65%, patients on warfarin with TTR <65%, patients on rivaroxaban 15 mg and 20 mg daily, and patients on dabigatran 110 mg twice daily. (C) The annual risk of ischemic stroke in Chinese AF patients on warfarin with TTR ≥65%, patients on warfarin with TTR <65%, patients on rivaroxaban 15 mg and 20 mg daily, and patients on dabigatran 110 mg twice daily.